Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
25,984,813
-
Share change
-
-1,430,258
-
Total reported value
-
$524,111,618
-
Price per share
-
$20.17
-
Number of holders
-
65
-
Value change
-
-$46,644,865
-
Number of buys
-
28
-
Number of sells
-
35
Institutional Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q1 2023
As of 31 Mar 2023,
Jade Biosciences, Inc. - COM (AVTE) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,984,813 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sofinnova Investments, Inc., Atlas Venture Life Science Advisors, LLC, BAKER BROS. ADVISORS LP, Cormorant Asset Management, LP, TCG Crossover Management, LLC, VR Adviser, LLC, ORBIMED ADVISORS LLC, GREAT POINT PARTNERS LLC, and Octagon Capital Advisors LP.
This page lists
65
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.